The recent withdrawal of Roctavian from the market has raised important questions for clinicians, patients, and healthcare systems involved in the management of haemophilia A. As the first approved gene therapy for adults with severe haemophilia A, Roctavian represented a significant milestone in the evolution of treatment options. This webinar will explore the clinical implications of its withdrawal, including considerations for patient management, ongoing monitoring of treated individuals, and the broader impact on the future of gene therapy in haemophilia.
Join us for an insightful discussion on what this development means for clinical practice and the haemophilia community.